A siRNA targets and inhibits a broad range of SARS‐CoV‐2 infections including Delta variantPan‐Chyr Yang, Yuan‐Fan Chin, Jun‐Tung Fang et al.|EMBO Molecular Medicine|2022Cited by 66
Neutralizing Monoclonal Antibodies Inhibit SARS-CoV-2 Infection through Blocking Membrane FusionChia‐Jung Li, Shih‐Chung Chang, Tai‐Ling Chao et al.|Microbiology Spectrum|2022Cited by 34
Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccinationWang‐Huei Sheng, Sui‐Yuan Chang, Pin‐Hung Lin et al.|Journal of the Formosan Medical Association|2022Cited by 28
Correlation of adverse effects and antibody responses following homologous and heterologous COVID19 prime-boost vaccinationsAristine Cheng, Shan‐Chwen Chang, Ming‐Ju Hsieh et al.|Journal of the Formosan Medical Association|2022Cited by 14
Immunogenicity and safety of third-dose mRNA COVID-19 vaccines in healthy adults previously vaccinated with two doses of the ChAdOx1 vaccineWang‐Huei Sheng, Si‐Man Ieong, Pin‐Hung Lin et al.|Journal of the Formosan Medical Association|2022Cited by 12